Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9663-9670

  Deng, Xuehong ^a   Liu, Han ^a   Huang, Jiaoti ^b   Cheng, Liang ^c   Keller, Evan T ^d   Parsons, Sarah J ^e   Hu, Chang Deng ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANDROGEN; BETA TUBULIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOCETAXEL; HISTONE H3;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CLONE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; NEUROSECRETORY CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ACTIVATING TRANSCRIPTION FACTOR 2; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOPLASM; DISEASE PROGRESSION; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 57149095259     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2229     Document Type: Article

References (50)

1. Ganswindt U, Paulsen F, Anastasiadis AG, Stenzl A, Bamberg M, Belka C. 70 Gy or more: which dose for which prostate cancer? J Cancer Res Clin Oncol 2005;131:407-19.
2. Allen GW, Howard AR , J arrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007;110:1405-16.
3. Daneshmand S, Quek ML, Pinski J. Neuroendocrine differentiation in prostate cancer. Cancer Ther 2005;3:383-96.
4. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN, Jr., Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007;10:6-14.
5. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14:287-300.
6. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-47.
7. Deeble PD, Cox ME, Frierson HF, Jr., et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663-72.
8. Nakada SY, di Sant'Agnese PA, Moynes RA, et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967-70.
9. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001;12 Suppl 2:S141-4.
10. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002;53:118-23.
11. 2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 2004;11:321-30.
12. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999;59:3821-30.
13. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
14. Brindle PK, Montminy MR. The CREB family of transcription activators. Curr Opin Genet Dev 1992;2:199-204.
15. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999;68:821-61.
16. Montminy MR, Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 1987;328:175-8.
17. Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP. Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 2006;8:523-33.
18. Unni E, Sun S, Nan B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-68.
19. Canaff L, Bevan S, Wheeler DG, et al. Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene. Endocrinology 1998;139:1184-96.
20. Kim J, Jia L, Stallcup MR, Coetzee GA. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 2005;34:107-18.
21. Johannessen M, Moens U. Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases. Front Biosci 2007;12:1814-32.
22. Hai TW, Liu F, Coukos WJ, Green MR. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 1989;3:2083-90.
23. Maekawa T, Sakura H, Kanei-Ishii C, et al. Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J 1989;8:2023-8.
24. Wagner EF. AP-1-Introductory remarks. Oncogene 2001;20:2334-5.
25. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
26. Gueorguiev VD, Cheng SY, Sabban EL. Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells. J Biol Chem 2006;281:10188-95.
27. Ionescu AM, Drissi H, Schwarz EM, et al. CREB Cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter. J Cell Physiol 2004;198:428-40.
28. Ionescu AM, Schwarz EM, Zuscik MJ, et al. ATF-2 cooperates with Smad3 to mediate TGF-β effects on chondrocyte maturation. Exp Cell Res 2003;288:198-207.
29. Niwano K, Arai M, Koitabashi N, et al. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1036-42.
30. Flint KJ, Jones NC. Differential regulation of three members of the ATF/CREB family of DNA-binding proteins. Oncogene 1991;6:2019-26.
31. Hay CW, Ferguson LA, Docherty K. ATF-2 stimulates the human insulin promoter through the conserved CRE2 sequence. Biochim Biophys Acta 2007;1769:79-91.
32. Ricote M, Garcia-Tunon I, Bethencourt F, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006;208:401-7.
33. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO J 2006;25:1058-69.
34. Paulmurugan R, Gambhir SS. Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal Chem 2005;77:1295-302.
35. Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998;242:540-7.
36. Reusch JE, Colton LA, Klemm DJ. CREB activation induces adipogenesis in 3T3-1 cells. Mol Cell Biol 2000;20:1008-20.
37. Barco A, Alarcon JM, Kandel ER. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 2002;108:689-703.
38. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008;101 Suppl 2:11-5.
39. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12 Suppl 2:S135-40.
40. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol 2007;29:128-38.
41. Yuan TC, Veeramani S, Lin FF, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 2006;13:151-67.
42. Ismail AH, Landry F, Aprikian AG, Chevalier S. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 2002;51:117-25.
43. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-37.
44. Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489-95.
45. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-9.
46. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase α signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003;22:6704-16.
47. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42:186-95.
48. Yang X, Chen MW, Terry S, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 2005;65:5263-71.
49. Karasewski L, Ferreira A. MAPK signal transduction pathway mediates agrin effects on neurite elongation in cultured hippocampal neurons. J Neurobiol 2003;55:14-24.
50. Aletta JM, Greene LA. Growth cone configuration and advance: a time-lapse study using video-enhanced differential interference contrast microscopy. J Neurosci 1988;8:1425-35.